Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma.
Indian J Pediatr
;
2009 Nov; 76(11): 1131-1135
Artigo
em Inglês
| IMSEAR
| ID: sea-142423
ABSTRACT
Objective. To compare efficacy and tolerability of levosalbutamol (Group 1) and racemic salbutamol (Group 2) for the treatment of acute exacerbation of asthma in children age 5 to 18 yr. Methods. A randomized double blind clinical study involving 60 children was undertaken between October ’06 to December ’07. Results. The following baseline clinical characteristic were recorded initially and after giving 3 nebulizations at 20 min intervals in the Ist hour of presentation viz respiratory rate (RR), heart rate (HR), oxygen saturation in room air SPO2, PEFR (peak expiratory flow rate), serum K+ level and asthma score. In Group 1 patients (levosalbutamol), there was significant increment in SPO2 and PEFR (P<0.05) values with decrease in tachypnea and asthma score while no significant difference was found in pre and post treatment HR & Serum K+ levels. In Group 2 patients although there was clinical improvement in terms of SPO2, PEFR, RR and asthma score, it resulted in significant tachycardia and decrease in K+ levels. Conclusion. Levosalbutamol appears to be more efficacious than racemic salbutamol in terms of improvement in PEFR, SPO2 and asthma score while deleterious effects of tachycardia and fall in serum K+ were seen with racemic salbutamol.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Potássio
/
Asma
/
Índice de Gravidade de Doença
/
Broncodilatadores
/
Feminino
/
Humanos
/
Esquema de Medicação
/
Criança
/
Pré-Escolar
/
Método Duplo-Cego
Tipo de estudo:
Ensaio Clínico Controlado
Idioma:
Inglês
Revista:
Indian J Pediatr
Ano de publicação:
2009
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS